ARQ-151 cream 0.3%

DRUG2 trials

Sponsors

Arcutis Biotherapeutics, Inc.

Conditions

Plaque PsoriasisPsoriasis

Phase 2

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)

CompletedNCT04655313

Arcutis Biotherapeutics, Inc.Plaque Psoriasis, Psoriasis

Start: 2020-11-30End: 2022-01-12Updated: 2023-12-15

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)

CompletedNCT04746911

Arcutis Biotherapeutics, Inc.Plaque Psoriasis, Psoriasis

Start: 2021-03-01End: 2022-05-11Updated: 2026-08-07

Related Papers

Early Evidence of Safety, Clinical Benefit, and Pharmacokinetics of Roflumilast Cream 0.3% Once Daily for Treatment of Mild or Moderate Plaque Psoriasis in Children Aged 2–11 Years

Pediatric Dermatology2025-08-27

Notice of Retraction and Replacement. Ellison-Barnes et al. Trends in Obesity Prevalence Among Adults Aged 18 Through 25 Years, 1976-2018. <i>JAMA</i>. 2021;326(20):2073-2074

JAMA2023-02-214 citations